Biogen | BIIB - Interest Expense On Debt



Biogen reported $59.8M in Interest Expense on Debt for its fiscal quarter ending in September of 2024.

Interest Expense On Debt Change Date
AbbVie USD 591M 135M Sep/2024
ALKERMES USD 6M 50K Sep/2024
Amgen USD 90.88B 24M Sep/2024
Bayer 642M 589.2M Sep/2024
Biogen USD 59.8M 1.5M Sep/2024
BioMarin Pharmaceutical USD 2.97M 602K Sep/2024
Bristol-Myers Squibb USD 505M 20M Sep/2024
Eli Lilly USD 144.9M 38.7M Sep/2024
Gilead Sciences USD 238M 1000K Sep/2024
Incyte USD 774K 117K Sep/2024
Merck USD 330M 20M Sep/2024
Moderna USD 15.8B 15.8B Sep/2024
Neurocrine Biosciences USD 1.1M 0 Mar/2024
Novartis USD 264M 18M Sep/2024
Pfizer USD 784M 6M Sep/2024
PTC Therapeutics USD 1.84B 1.8B Sep/2024
Regeneron Pharmaceuticals USD 13.8M 1000K Sep/2024
Sarepta Therapeutics USD 4.92M 86K Sep/2024
Teva Pharmaceutical Industries USD 241M 9M Jun/2024
Ultragenyx Pharmaceutical 15.71M 14.11M Sep/2024
United Therapeutics USD 10.1M 1.5M Sep/2024
Vertex Pharmaceuticals USD 7.5M 2.4M Sep/2024